CoChat

SNMMI Procedure Standard/EANM Practice Guideline for SSTR PET: Imaging Neuroendocrine Tumors

Hope, Thomas A., Allen-Auerbach, Martin, Bodei, Lisa, Calais, Jeremie, Dahlbom, Magnus, Dunnwald, Lisa K., Graham, Michael M., Jacene, Heather A., Heath, Courtney Lawhn, Mittra, Erik S., Wright, Chadwick L., Fendler, Wolfgang P., Herrmann, Ken, Taïeb, David, Kjaer, Andreas · 2023 · Journal of Nuclear Medicine
Cited by 144

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2967/jnumed.122.264860

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Research works printed but not linked: 44

  1. 10.1200/JCO.2009.22.8510 · DOI · Paper page
  2. 10.1056/NEJMoa1316158 · DOI · Paper page
  3. 10.2967/jnumed.117.202275 · DOI · Paper page
  4. 10.2967/jnumed.120.257808 · doi:10.2967/jnumed.120.257808
  5. 10.1111/his.13975 · DOI · Paper page
  6. 10.1530/ERC-17-0005 · DOI
  7. 10.1007/s00259-011-2031-6 · DOI · Paper page
  8. Society of Nuclear Medicine and Molecular Imaging Technologist Section. Nuclear Medicine Technologist Scope of Practice and Performance Standards. 2nd Edition. Amazon aws website. http://s3.amazonaws.com/rdcms-snmmi/files/production/public/NMT%20Scope%20of%20Practice%20and%20Performance%20Standards%202nd%20Ed-2022%20Complete-Approved_6-9-22.pdf. Approved June 9, 2022. Accessed December 1, 2022.
  9. Bozkurt, 2017, Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F-DOPA, Eur J Nucl Med Mol Imaging., 44, 1588, 10.1007/s00259-017-3728-y · doi:10.1007/s00259-017-3728-y
  10. Aalbersberg, 2019, Influence of lanreotide on uptake of 68Ga-DOTATATE in patients with neuroendocrine tumours: a prospective intra-patient evaluation, Eur J Nucl Med Mol Imaging., 46, 696, 10.1007/s00259-018-4117-x · DOI
  11. 10.2967/jnumed.119.226332 · doi:10.2967/jnumed.119.226332
  12. 10.2967/jnumed.117.192203 · DOI
  13. Kong, 2016, Initial experience with gallium-68 DOTA-octreotate PET/CT and peptide receptor radionuclide therapy for pediatric patients with refractory metastatic neuroblastoma, J Pediatr Hematol Oncol., 38, 87, 10.1097/MPH.0000000000000411 · DOI
  14. Abongwa, 2017, Safety and accuracy of 68Ga-DOTATOC PET/CT in children and young adults with solid tumors, Am J Nucl Med Mol Imaging., 7, 228
  15. 10.2967/jnumed.120.244509 · doi:10.2967/jnumed.120.244509
  16. 10.1007/s00261-015-0409-9 · doi:10.1007/s00261-015-0409-9
  17. 10.2967/jnumed.112.114165 · DOI
  18. 10.2967/jnumed.116.180430 · DOI · Paper page
  19. 10.1097/RLU.0b013e31825b2555 · doi:10.1097/rlu.0b013e31825b2555
  20. Virgolini, 2016, Current knowledge on the sensitivity of the 68Ga-somatostatin receptor positron emission tomography and the SUVmax reference range for management of pancreatic neuroendocrine tumours, Eur J Nucl Med Mol Imaging., 43, 2072, 10.1007/s00259-016-3395-4 · DOI
  21. 10.1016/S0140-6736(78)92181-5 · DOI
  22. Mackie, 1990, Somatostatin receptors are restricted to a subpopulation of osteoblast-like cells during endochondral bone formation, Development., 110, 1233, 10.1242/dev.110.4.1233 · DOI
  23. 10.1152/ajpendo.00048.2003 · DOI · Paper page
  24. Hope, 2019, 111In-pentetreotide scintigraphy versus 68Ga-DOTATATE PET: impact on Krenning scores and effect of tumor burden, J Nucl Med., 60, 1266, 10.2967/jnumed.118.223016 · DOI
  25. Kratochwil, 2015, SUV of [68Ga]DOTATOC-PET/CT predicts response probability of PRRT in neuroendocrine tumors, Mol Imaging Biol., 17, 313, 10.1007/s11307-014-0795-3 · DOI · Paper page
  26. Werner, 2018, SSTR-RADS version 1.0 as a reporting system for SSTR-PET imaging and selection of potential PRRT candidates: a proposed standardization framework, J Nucl Med., 59, 1085, 10.2967/jnumed.117.206631 · DOI
  27. Öksüz, 2014, Peptide receptor radionuclide therapy of neuroendocrine tumors with 90Y-DOTATOC: is treatment response predictable by pre-therapeutic uptake of 68Ga-DOTATOC?, Diagn Interv Imaging., 95, 289, 10.1016/j.diii.2013.07.006 · DOI
  28. 10.1245/s10434-015-4471-x · doi:10.1245/s10434-015-4471-x
  29. Reubi, 1990, Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas, Cancer Res., 50, 5969
  30. Graf, 2020, Prognostic significance of somatostatin receptor heterogeneity in progressive neuroendocrine tumor treated with Lu-177 DOTATOC or Lu-177 DOTATATE, Eur J Nucl Med Mol Imaging., 47, 881, 10.1007/s00259-019-04439-9 · DOI
  31. Werner, 2019, Pre-therapy somatostatin receptor-based heterogeneity predicts overall survival in pancreatic neuroendocrine tumor patients undergoing peptide receptor radionuclide therapy, Mol Imaging Biol., 21, 582, 10.1007/s11307-018-1252-5 · DOI
  32. Werner, 2017, Survival prediction in patients undergoing radionuclide therapy based on intratumoral somatostatin-receptor heterogeneity, Oncotarget., 8, 7039, 10.18632/oncotarget.12402 · DOI
  33. 10.1002/cncr.23469 · DOI · Paper page
  34. Hindié, 2017, The NETPET Score: combining FDG and somatostatin receptor imaging for optimal management of patients with metastatic well-differentiated neuroendocrine tumors, Theranostics., 7, 1159, 10.7150/thno.19588 · DOI
  35. Binderup T Knigge U Johnbeck CB . 18F-FDG-PET is superior to WHO grading as prognostic tool in neuroendocrine neoplasms and useful in guiding peptide receptor radionuclide therapy: a prospective 10-year follow-up study of 166 patients. J Nucl Med. 2021; 62:808–815. · DOI
  36. 10.1102/1470-7330.2010.9007 · DOI
  37. Chan, 2017, Dual somatostatin receptor/FDG PET/CT imaging in metastatic neuroendocrine tumours: proposal for a novel grading scheme with prognostic significance, Theranostics., 7, 1149, 10.7150/thno.18068 · DOI · Paper page
  38. 10.2967/jnumed.106.035667 · DOI · Paper page
  39. 10.2967/jnumed.115.156539 · DOI
  40. 10.1200/JCO.2015.64.0987 · DOI · Paper page
  41. Hartmann, 2009, Radiation exposure of patients during 68Ga-DOTATOC PET/CT examinations [in German], Nucl Med (Stuttg)., 48, 201
  42. 10.2967/jnumed.111.101469 · DOI · Paper page
  43. Brix, 2005, Radiation exposure of patients undergoing whole-body dual-modality 18F-FDG PET/CT examinations, J Nucl Med., 46, 608
  44. Kratochwil, 2015, Comparison of 68Ga-DOTATOC biodistribution in patients with and without splenectomy, Q J Nucl Med Mol Imaging., 59, 116

Cited by

Metadata

Authors
Hope, T. A., Allen-Auerbach, M., Bodei, L., Calais, J., Dahlbom, M., Dunnwald, L. K., Graham, M. M., Jacene, H. A., Heath, C. L., Mittra, E. S., Wright, C. L., Fendler, W. P., Herrmann, K., Taïeb, D., & Kjaer, A.
Venue
Journal of Nuclear Medicine
Published
2023-02
Volume
64
Issue
2
Pages
204-210
ISSN
  • 0161-5505
  • 2159-662X
Cited by
144
References
3
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.